Compare Merck & Co., Inc. (MRK) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Zillow Group Inc Class C — how do they compare? Merck & Co., Inc. trades at $126.26 (market cap $307.25B), while Zillow Group Inc Class C trades at $31.8 (market cap $7.54B). The key difference: Merck & Co., Inc. is far larger — about 40.7× Zillow Group Inc Class C's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals.
| MRK | Z | |
|---|---|---|
Market Cap | $307.25B | $7.54B |
Sector | Health | Media |
52-Week High | $129.52 | $90.35 |
52-Week Low | $77.60 | $29.41 |
Enterprise Value | $350.66B | $7.19B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Zillow Group (Z) trades at $33.03, down 2.58% amid legal headwinds, with technicals neutral and fundamentals showing improving profitability. Revenue grew to $2.58B in 2025 with net income turning positive at $23M, though valuation multiples remain elevated with a P/E of 132.04. The stock faces significant legal overhang from multiple class-action lawsuits alleging securities fraud related to an anticompetitive agreement.
The outlook is cautious; while earnings beat expectations in two recent quarters and analyst consensus targets $57.67, near-term risks from litigation and a high P/E ratio temper upside potential. Investment appeal hinges on legal resolution and sustained margin expansion beyond current modest levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
